Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient

This double-blinded randomized controlled trial aims to investigate the effect of intraoperative dexmedetomidine administration on early flap viability and microvascular integrity in cancer patients undergoing elective microvascular reconstructive surgery. The primary outcome is clinical flap viability within 48 hours postoperatively, assessed using a standardized scoring system based on flap color, temperature, capillary refill time, and tissue turgor. Secondary outcomes include the evaluation of biomarkers related to endothelial glycocalyx degradation (syndecan-1), oxidative stress (SOD-1), inflammation (IL-6, IL-10), thrombosis (PAI-1), and angiogenesis (VEGF), as well as microcirculatory assessment using Sidestream Dark Field (SDF) imaging. The study is designed to determine whether dexmedetomidine improves early surgical outcomes by modulating pathophysiological processes involved in microvascular flap success.

NCT Number	NCT06993740
Lead Sponsor	Dharmais National Cancer Center Hospital
Conditions	Flap Monitoring, Inflammation, Thrombosis, Oxidative Stress, Glycocalyx, Anesthesia, Surgery, Flap Ischemia +3 more
Enrollment	60 participants
Start Date	2025-06-10
Primary Completion	2026-03-06 (estimated)
Study Completion	2026-03-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-31